)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Poltreg
Poltreg (PTG) investor relations material
Poltreg Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary9 Sep, 2026
Executive summary
Continued focus on advanced clinical-stage Treg cell therapies for autoimmune diseases, with ongoing R&D and no significant revenue generation beyond hospital exemption sales.
Maintained strong cash position, supported by public grants and a successful share issue in March 2026.
Strategic milestones include new R&D project funding and a regulatory partnership for EU drug registration.
Financial highlights
Revenue from product sales remained flat at 240k PLN for H1 2026, unchanged year-over-year.
Net loss for H1 2026 was 12,429k PLN, an improvement from 13,968k PLN in H1 2025.
Operating loss narrowed to 12,094k PLN from 14,162k PLN year-over-year.
Cash and equivalents at period end were 22,637k PLN, up from 17,785k PLN at 2025 year-end.
Total assets at 30 June 2026 were 75,142k PLN, down from 87,313k PLN a year earlier.
Outlook and guidance
Management forecasts the need for additional funding to support full R&D plans, with a planned share issue as the primary source.
Flexibility in project spending and cost control measures are in place to extend liquidity if needed.
No material uncertainty identified regarding going concern for the forecast period.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Poltreg
- Global TREG therapy leader with proven technology, strong pipeline, and US expansion strategy.PTG
Investor presentation - Net loss widened to 6.8 million PLN as R&D accelerated, with major clinical and financing milestones achieved.PTGQ1 2026
- Net loss widened to 25.99m PLN as R&D and operating costs rose; major U.S. and EU regulatory progress.PTGQ4 2025
- Net loss nearly doubled as revenue fell, but key clinical and grant milestones were achieved.PTGQ2 2024
- Revenue dropped sharply as clinical and regulatory progress accelerated, with losses offset by strong cash and grants.PTGQ4 2024
- Losses increased as revenue fell, but clinical and patent milestones position the pipeline for future growth.PTGQ3 2024
- Net loss widened on higher R&D costs, but clinical and regulatory milestones advanced.PTGQ3 2025
- Q1 2025 marked higher losses, no sales, and key advances in TREG therapy R&D and partnerships.PTGQ1 2025
- Net loss deepened, cash reserves fell, but major clinical and regulatory milestones were achieved.PTGQ2 2025
Next Poltreg earnings date
Q3 202618 Nov, 2026
Poltreg
Next Poltreg earnings date
Q3 202618 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage